Biocon Founder Tells Karnataka to Create Special Investment Fund for Biotech

June 20, 2026 4 min read

Dr. Kiran Mazumdar-Shaw, founder of Biocon Limited, has called on the Karnataka government to establish dedicated investment mechanisms specifically designed to support the biotechnology sector. The recommendation comes as the state seeks to maintain its position as India's leading biotech hub. Speaking at a recent industry forum, the pharma entrepreneur emphasized the need for policy-level intervention to fuel growth in what she described as a strategically important industry.

Call for Sector-Specific Investment Vehicles

Mazumdar-Shaw's recommendation centres on creating specialised funding instruments that cater specifically to biotech companies. Unlike generic investment schemes, such mechanisms would address the unique challenges faced by firms engaged in drug discovery, clinical research, and biomedical innovation. The proposal reflects concerns about the high capital requirements and long development cycles that characterise the biotechnology sector.

Biocon, headquartered in Bengaluru, has grown into one of India's largest biopharmaceutical companies under Mazumdar-Shaw's leadership. The company produces affordable biopharmaceuticals and active pharmaceutical ingredients, exporting to over 120 countries. Its success story has made Mazumdar-Shaw one of India's most recognisable voices on biotechnology policy.

Why Karnataka's Biotech Sector Demands Special Attention

Karnataka accounts for a substantial share of India's biotechnology revenue, with Bengaluru serving as the operational base for hundreds of biotech firms. The state government has previously supported the sector through grants, tax incentives, and infrastructure development at biotech parks. However, Mazumdar-Shaw argues that current mechanisms fall short of what the industry requires to scale up.

The sector supports thousands of skilled jobs across research laboratories, manufacturing facilities, and contract research organisations. Young professionals from across India relocate to Bengaluru for careers in biotech, contributing to the local economy through housing, retail, and services. Any policy change affecting this ecosystem has ripple effects throughout the city's service economy.

Global Competition Intensifies

The push for dedicated investment mechanisms reflects broader global trends in biotechnology funding. Countries including Singapore, South Korea, and several European nations have created sovereign wealth funds and public-private partnerships specifically for biotech. These programmes aim to attract talent and accelerate commercialisation of research discoveries.

Industry observers note that Indian biotech companies often struggle to secure late-stage funding when moving from research to commercial production. Venture capital interest exists, but many promising firms seek government-backed instruments to de-risk their growth trajectories. Mazumdar-Shaw's recommendation directly addresses this funding gap.

Government Response and Industry Expectations

The Karnataka government's Department of IT, BT, and S&T oversees biotechnology policy in the state. Officials have acknowledged the need to review existing support structures in light of evolving industry requirements. Any new investment vehicle would likely require cabinet approval and coordination with financial regulatory bodies.

Industry associations have welcomed Mazumdar-Shaw's suggestion, viewing it as a catalyst for policy discussion. Smaller biotech firms, which often lack access to traditional bank financing, stand to benefit most from specialised investment products. The proposal also aligns with federal government initiatives to position India as a global biotech destination by 2030.

What Comes Next

The Karnataka government is expected to present its annual budget in the coming months, which could signal intentions regarding new sector-specific schemes. Industry stakeholders will be watching for any allocation towards biotechnology fund structures. If the state moves forward, officials would need to determine whether a new statutory body, a venture fund, or a co-investment mechanism best serves the sector's needs.

Whether Karnataka adopts Mazumdar-Shaw's recommendation could influence how other Indian states approach biotech promotion. The outcome will also signal the state's commitment to retaining its leadership position in a sector that contributes significantly to exports, employment, and healthcare innovation. Citizens and industry professionals alike will be tracking the budget deliberations closely for any concrete announcements.

Context: Karnataka's Biotech Journey

Karnataka established one of India's first biotech policies in the early 2000s, recognising the sector's potential for high-value economic activity. The Bangalore Bioinnovation Centre and various incubation facilities have supported startups through early development phases. Despite this head start, the state faces increasing competition from Hyderabad, Mumbai, and Pune for biotech investments.

Mazumdar-Shaw has previously advocated for policies that reduce import dependence for critical biological reagents and equipment. Her latest recommendation builds on this theme by calling for investment mechanisms that keep biotech innovation anchored in Karnataka rather than being attracted to other locations with more attractive funding environments.

Looking Ahead

The coming weeks will reveal whether Karnataka officials are prepared to act on Mazumdar-Shaw's suggestion. Industry sources indicate that a formal proposal could be submitted to the state government within the next quarter. If approved, such a fund could unlock growth for dozens of companies currently constrained by limited access to growth capital.

For Bengaluru's thriving biotech community, the stakes are clear: without strategic investment support, the city risks losing its competitive edge to better-funded alternatives. The outcome of this policy debate will shape Karnataka's biotechnology landscape for years to come.